Market Overview

UPDATE: Piper Jaffray Upgrades Amgen to Overweight on Continued Upside

Share:
Related AMGN
Attention Biotech Investors: Mark Your Calendar For These November PDUFA Dates
The Daily Biotech Pulse: KemPharm, FDA Nod For Merck, Clovis Q3 Miss, 3 Stocks To Debut
Cancer Research Highlight: RedHill Biopharma Sets Up Continued Invasion Into Cancer (Seeking Alpha)

Piper Jaffray upgraded its rating on Amgen (NASDAQ: AMGN) from Neutral to Overweight and increased its price target from $77 to $95.

Piper Jaffray commented, "We are upgrading AMGN to OW from Neutral and raising our price target to $95 from $77 following 2Q earnings that provided strong evidence of stabilization of the company's base businesses. In addition, the company announced advancement of three products into Phase III trials, two of which could be potential blockbusters (AMG145 and AMG785), that should drive long term growth. This combined with renewed fiscal discipline and willingness to increase dividend yield in line with major pharmaceutical companies should enable AMGN shares to continue to outperform."

Amgen closed at $77.96 on Thursday.

Latest Ratings for AMGN

DateFirmActionFromTo
Nov 2018CitigroupMaintainsNeutralNeutral
Oct 2018Morgan StanleyMaintainsOverweightOverweight
Oct 2018Morgan StanleyMaintainsOverweightOverweight

View More Analyst Ratings for AMGN
View the Latest Analyst Ratings

Posted-In: Piper JaffrayAnalyst Color Upgrades Pre-Market Outlook Analyst Ratings

 

Related Articles (AMGN)

View Comments and Join the Discussion!

Latest Ratings

StockFirmActionPT
ACBIKeefe Bruyette & WoodsUpgrades21.0
COTYBMO CapitalUpgrades12.0
ECCOppenheimerDowngrades0.0
VYGRRaymond JamesUpgrades0.0
ATNXJP MorganUpgrades15.0
View the Latest Analytics Ratings
Don't Miss Out!
Join Our Newsletter
Subscribe to:
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
Your weekly roundup of hot topics in the exciting world of fintech.
Thank You
for registering for Benzinga’s newsletters and alerts.
• The Daily Analysts Ratings email will be received daily between 7am and 10am.
• The Market in 5 Minutes email will be received daily between 7am and 8am.
• The Fintech Focus email will be received every Friday between 2pm and 5pm.

UPDATE: Apple Buys AuthenTec for $8/Share Cash

UPDATE: Sterne Agee Initiates Prospect Global Resource at Buy with $5 PT